COVID-19 Infections and Infestations
Conditions
Interventions
This is an observational retrospective matched cohort study using a series of datasets in England, accessible through National Health Services (NHS) England (formerly NHS Digital).
The overall study
groups at a greater risk of poor CO
Sponsors
Sanofi (France)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: This study will include all individuals aged 18 years or older who are eligible to receive a VidPrevtyn Beta vaccine.
Exclusion criteria
Exclusion criteria: Individuals <18 years and those who are ineligible to receive a VidPrevtyn Beta vaccine.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Vaccine effectiveness of VidPrevtyn Beta against hospitalisation due to laboratory-confirmed SARS-CoV-2 infection in patients who have received at least one additional dose of VidPrevtyn Beta as their last dose, compared with patients who have not received a booster dose measured using patient medical records within the same campaign period | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary outcome measures are measured using patient medical records: 1. Vaccine effectiveness of VidPrevtyn Beta against death due to laboratory-confirmed SARS-CoV-2 infection in patients who have received at least one additional dose of VidPrevtyn Beta as their last dose, compared with patients who have not received a booster dose within the same campaign period 2. Relative vaccine effectiveness of VidPrevtyn Beta against hospitalisation due to laboratory-confirmed SARS-CoV-2 infection in patients who have received at least one additional dose of VidPrevtyn Beta as their last dose, compared with patients who have received an mRNA booster dose within the same campaign period Exploratory outcome measures: 1. Vaccine effectiveness of VidPrevtyn Beta against hospitalisation due to laboratory-confirmed SARS-CoV-2 infection in patients who have received at least one additional dose of VidPrevtyn Beta as their last dose, compared with patients who have not received a booster dose within the same campaign period, stratified by: 1.1. Age groups 1.2. Gender 1.3. COVID-19 vaccination history 1.3.1. Compare by heterologous vs homologous (platform) history of vaccination 1.3.2. Compare by number of previous COVID-19 vaccine doses received 1.3.3. Subgroups of special interest (e.g. pregnant women, immunocompromised patients, frail patients with unstable health conditions and co-morbidities (eg, chronic obstructive pulmonary disease [COPD], diabetes, chronic neurological disease, cardiovascular disorders), patients with the autoimmune or inflammatory disorder) | — |
Countries
England, United Kingdom
Contacts
Public ContactMark Yates
Outcome results
None listed